STM JOURNALS

Trends in
Drug Delivery

ISSN: 2394-7268
Volume 12, Issue 2, 2025
May–August
DOI (Journal): 10.37591/TDD

https://journals.stmjournals.com/tdd

Review TDD

Pharmaceutical Bead Formulations: A Comprehensive Overview into Advanced Drug Delivery

Vedant Patel[1], P. N. Vaishnavi[1], Himanshu Solanki[2,*], Jaimin Kumar Patel[3]

Abstract

Pharmaceutical beads are a unique and flexible drug delivery vehicle that provides numerous possibilities to control the release of drugs, protect them, and increase their therapeutic performance. These beads make it possible to design several types of therapeutic regimens by incorporating active pharmaceutical ingredients in a polymeric or lipid matrix. This review discusses the bead technology in drug delivery from its inception to its present application, focusing on the most important changes in bead formulation and their application in the invention of new drugs. Beads are the most significant in sustained and controlled release formulations, which are associated with better patient compliance and fewer side effects, and can be used in the treatment of patients in a more personalized way.

Keywords: Pharmaceutical beads, ionotropic gelation, spray drying, modified drug release, personalized medication

INTRODUCTION TO PHARMACEUTICAL BEADS

Pharmaceutical beads are round, small-sized particles that are used as a drug dosage form. They are also known as pelletized dosage forms or multiparticulate systems. Pharmaceutical beads have gained significant importance in the field of drug delivery due to their versatile applications in improving the drug efficacy, patient compliance, and therapeutic outcome. They vary in size from a few µm to several mm, are small, and are prepared to enclose one or more active pharmaceutical ingredients (APIs) within a polymer or lipid matrix. The main objective of pharmaceutical beads is to control the release of a drug, enhance its stability, and improve the overall therapeutic efficacy while assuring patient compliance [1].

Pharmaceutic beads are commonly composed of three primary elements: the active drug, an inert core (most often sugar or microcrystalline cellulose), and excipients that encompass binders, coatings, or release-modifying agents [2].

These beads are available in a diameter range of 0.1–2 mm. Depending on the therapeutic requirement, beads can be formulated into capsules, sachets, or tablets. One of the major advantages of beads is that they can maintain drug release by customizable coating techniques, over traditional single-unit tablets or capsules. Pharmaceutical beads have been widely used in the development of extended or delayed release formulations [3].

Being very flexible and efficient, beads as a pharmaceutical delivery system are greatly versatile. Their application enhances therapeutic

***Author for Correspondence**
Himanshu Solanki
E-mail: drhimanshusolanki7ssrcp@gmail.com

[1]PG Research Scholar, Department of Pharmaceutics, SSR College of Pharmacy (Permanently Affiliated to Savitribai Phule Pune University), Sayli-Silvassa Road, Sayli, Silvassa, Union Territory of Dadra Nagar Haveli and Daman Diu, India.
[2]Professor, Department of Pharmaceutics, SSR College of Pharmacy (Permanently Affiliated to Savitribai Phule Pune University), Sayli-Silvassa Road, Sayli, Silvassa, Union Territory of Dadra Nagar Haveli and Daman Diu, India.
[3]R&D, Navinta LLC, Ewing, NJ 08628, USA.

Received date: April 03, 2025
Accepted date: April 09, 2025
Published date: July,25,2025

Citation: Vedant Patel, P. N. Vaishnavi, Himanshu Solanki, Jaimin Kumar Patel. Pharmaceutical Bead Formulations: A Comprehensive Overview into Advanced Drug Delivery. Trends in Drug Delivery. 2025; 12(2): 78–100p.

outcomes through modifications of drug release profiles, improvement of compliance in patients, and reduction of side effects – they are, therefore, key instruments in modern pharmacy practice. Once technology advancement evolves, the role that beads play within personalized medicine and targeted drug delivery will expand more [4].

HISTORY OF BEAD FORMULATION

Being accelerated because of the fast developments in technology, material science, and understanding of drug delivery mechanisms over the last few hundred years, the history of pharmaceutical bead formulation has witnessed several aspects with respect to formulation and understanding of multiple particulate bead formulations. Bead formulations, mainly multiple-particulate drug delivery systems, have drawn significant attention in pharmaceutical sciences as a controlled, sustained, or targeted release of drugs. Following are some details on these key milestones in the history of pharmaceutical bead formulation.

Ancient Origins of Bead-Like Dosage Forms

The early history of pharmaceutical beads dates to ancient Egypt, Greece, and China, where herbal remedies were compressed into small and ingestible shapes. While these early formulations lacked precise dosing and drug release control, they laid the foundation for the concept of distinct medication doses [5, 6].

Development of Pills and Granules (17th–19th Century)

In the 17th and 18th centuries, granulation techniques advanced, producing pills, granules, and powders. Granules, formed by binding powdered medicine with liquids or binders, were early precursors to modern pharmaceutical beads [7, 8]. Early apothecaries manually blended active ingredients with excipients, like honey or syrup, to form pills, resulting in non-uniform sizes and inconsistent dosing [9]. By the 19th century, sugar-coated pills emerged to mask bitterness, paving the way for advanced coatings that later enabled controlled drug release [10].

The Birth of Multiparticulate Systems (1960s)

In the 1960s, multiparticulate drug delivery gained popularity, using small drug-filled particles instead of single large doses, allowing for more controlled and consistent release [11, 12].

Advancements in coating technology introduced polymers, like ethyl cellulose and HPMC, enabling sustained and extended-release drug formulations [13].

Technological Advancements in the 1970s and 1980s

In the 1970s, extrusion-spheronization revolutionized bead production by shaping wet drug-excipient masses into uniform, dense pellets, ensuring scalable and consistent drug release [14].

In the 1970s and 1980s, fluidized bed coating improved drug layering on beads, enabling precise, controlled release and advancing multiparticulate drug systems [15]. In the 1980s, bead-based controlled-release drugs improved pharmacokinetics, reducing side effects and enhancing compliance, with major firms like SmithKline Beecham and Pfizer leading the market [16].

Widespread Commercialization and Innovation (1990s–Early 2000s)

In the 1990s and 2000s, beads were used in combination therapies, incorporating multiple drugs into a single form, with each drug layered on different beads for controlled or delayed release [17]. In the 1990s and 2000s, pharmaceutical beads were increasingly used in modified release systems, offering pulsatile, delayed, or extended release. Advances in polymer science enabled coatings that responded to environmental triggers, enhancing targeted drug delivery [18].

Beads with enteric coatings protect drugs from gastric acid, allowing release in the intestine, especially for drugs that degrade in acid or irritate the stomach [19].

Present-Day Innovations and Future Trends (2010s–Present)

Nanoparticles and microparticles are gaining interest as advanced drug delivery systems, offering more precise release and targeting at the nanoscale, enhancing the principles of multiparticulate systems [20]. 3D printing in pharmaceuticals enables tailor-made bead formulations for personalized medicine, allowing precise drug loading and controlled release [21]. Advanced coatings, like smart polymers and responsive coatings, enable targeted drug release by reacting to physiological conditions, optimizing bead formulations [22].

Bead technology remains key in controlled-release drug delivery, improving compliance and stability while researchers explore new materials and methods [23].

IMPORTANCE IN DRUG DELIVERY

Pharmaceutical beads have been found to be very useful in improving the bioavailability of drugs, particularly drug products with low solubility and narrow therapeutic windows. Beads control drug release, maintain therapeutic drug levels, minimize side effects, and make drug administration more effective and patient compliant [24, 25].

The multiparticulate nature of beads can improve the distribution of the drug throughout the gastrointestinal tract, enhancing absorption and efficacy. Additionally, beads can be engineered for targeted delivery to specific tissues or organs, further optimizing therapeutic outcomes [26].

Factors Affecting the Formulation of Beads



Figure 1. Schematic representation of factors affecting the beads formulation.

Physicochemical Factors [2–5]

1. Since most drugs are weak bases or acids, it is challenging to incorporate them into mechanisms for prolonged release. It might be challenging to include medications with low water solubility and challenging to delay the dissolution of medications with high water solubility and a quick rate of dissolution. Absorbing quickly and increasing blood medication concentration is possible when a medicine has high water solubility since it may dissolve in water or gastrointestinal fluid. pH-dependent solubility can also be problematic for prolonged release formulations, especially in the physiological pH range. The solubility, dissolution, and intestinal permeability contributions to oral absorption are estimated using the biopharmaceutical categorization system (BCS). Sustained release dosage forms are not recommended for Class III and IV medications, because solubility problems with substances containing less than 0.1 mg/ml are substantial (Figure 1) [27–30].
2. *Partition Coefficient (P (o/w)):* The percentage of medication in an oil phase relative to that in an adjacent aqueous phase is known as the partition coefficient. Because biological membranes are lipophilic, drugs that pass through them have high bioavailability if the drug's partition coefficient is affected. Because they won't partition out of the lipid membrane once they are inside, medications with lower partition coefficients are inappropriate for oral CR drug delivery systems, while drugs with larger partition coefficients are likewise inappropriate for oral SR drug delivery systems [31].

3. *Medication pKa and Ionization at Normal pH:* Oral sustained release drug delivery systems are not the best option for medications that are mostly found in ionized form. Unionized medications absorb effectively, while ionized drug penetration is minimal because ionized drug absorbs at a rate three to four times lower than that of unionized pharmaceuticals. For optimal positive absorption, the ionization constant ranges for acidic drugs are around 3.0–7.5, and for basic drugs are approximately 7.0–11.0. The drug will be unionized at the location at a degree of 0.1%–5.0% [27].
4. *Medication Stability:* Upon oral administration, drugs experience both enzymatic degradation and acid/base hydrolysis. Drugs that are unstable in the stomach and take longer to reach the complete GI tract may degrade at a slower rate if they are in a solid form. The drug's bioavailability may be reduced if it is taken in a prolonged-release dose form that is unstable in the small intestine. This happens because the small intestine receives a larger dose of the medication and experiences higher levels of breakdown [8–10].
5. *Molecular Size and Diffusivity:* The size and form of the membrane's cavities affect diffusivity. A medication with an intermediate molecular weight has a diffusion coefficient of 100–400 Daltons and a flexible polymer range of 10^{-6}–10^{-9} cm^2/sec. In many polymers, the diffusion coefficient for medications more than 500 Daltons is very low, often less than 10–12 cm^2/sec. Proteins and peptides are examples of medications whose release rates from dosage forms are challenging to regulate [31].
6. *Biological Factor:* The absorption behavior of a drug can impact its suitability as an extended-release product. Sustained release products aim to control the delivery system, ensuring that the rate of release is slower than the rate of absorption. Low absorption rate constants are poor candidates due to factors, such as poor water solubility, small partition coefficient, acid hydrolysis, metabolism, or absorption site. Drug distribution in tissues also affects drug elimination kinetics, with a high apparent volume of distribution affecting the rate of elimination. Formulation scientists must consider the drug's disposition for sustained release products. Extensively metabolized drugs are not suitable for SR delivery systems, as they may struggle to maintain constant blood levels. Drugs metabolized before absorption in the lumen or intestinal tissues may show decreased bioavailability from sustained-release systems. Enzymes in intestinal walls are saturated, and systems should be designed to allow for more complete conversion of the drug to its metabolite [29].
7. *Half-Life:* A drug's half-life is a measure of how long it stays in the body. The dosage form may contain an excessively high amount of the medicine if it has a short half-life (less than two hours). However, when given in a typical dosage, drugs with an elimination half-life of eight hours or longer are adequately regulated in the body, negating the need for a sustained-release drug delivery system. A medication with a half-life of three to four hours is ideal for drug delivery system formulation [28–30].
8. *Therapeutic Index:* It is not appropriate to include medications with poor therapeutic indices in sustained-release formulations. Dosage dumping can happen if the body's mechanism malfunctions, which might result in toxicity [29].
9. *Size of Dose:* A medication is a less good option for SRDDS if its dose in the normal dosing form is high. This is because a unit dosage sustained-release oral formulation would grow too large to easily deliver [31].
10. *Absorption Window:* When taken orally, certain medications exclusively absorb from a particular area of the digestive system. We call this section the absorption window. Additionally, these applicants are unfit for SRDDS [7].
11. *Plasma Concentration Response Relationship:* Pharmacological action is typically more related to plasma drug concentration than to dosage. However, medications with pharmacological action that is not reliant on plasma concentrations are not good choices for oral SR drug delivery modes (Table 1) [31].

TYPES OF PHARMACEUTICAL BEADS

Table 1. Describing the various types of beads.

S. N.	Type of Beads	Description	Reference
Based on Release Mechanism			
1.	Osmotic beads	Contains an osmotic agent that draws water into the bead, and through this process, the drug is released.	[32].
2.	Magnetic beads	Thus, external magnetic fields can control them and thus aid targeted drug delivery.	[33].
3.	Light-responsive beads	The release of the drug is governed by light, thus paving the way for regulated release and space-time targeting.	[34].
4.	pH-sensitive beads	Deliver the drug at specific pH levels, for example, in the stomach or intestine.	[35].
Based on Application			
1.	Vaccine beads	It can be used as an encapsulation agent that provides sustained release with enhanced immune response.	[36].
2.	Gene delivery beads	It can also be used for gene therapy by direct delivery of DNA or RNA.	[37].
3.	Imaging beads	Filled with contrast agents, it can be used for diagnostic imaging to be possible through their usage.	[38].
4.	Tissue engineering beads	It acts as a scaffold for tissue regeneration.	[39].
Specialized Beads			
1.	Microparticles	They are even smaller than beads and are used in fast drug delivery or targeted delivery.	[40].
2.	Nanoparticles	Still smaller, they are used for enhanced penetration of drugs with controlled release.	[41].
3.	Liposomes	These vesicles are made of phospholipids. They are used for the encapsulation of both hydrophilic as well as hydrophobic drugs.	[42].
4.	Micelles	Self-assembly structures formed by surfactants are used to solubilize and achieve controlled release of hydrophobic drugs.	[43].
Based on Composition			
I.	*Polymer Beads*		
1.	Alginate beads	Generally, used in controlled release and targeted delivery, specifically to the gastrointestinal tract.	[44].
2.	Chitosan beads	Biodegradable and positively charged: used in mucosal drug delivery.	[45].
3.	Gelatin beads	Biodegradable and versatile: can be utilized in a range of drug delivery applications.	[46].
4.	Polyvinyl alcohol (PVA) beads	It's applied in controlled release with the capacity for modification of its properties.	[47].
II.	*Inorganic Beads*		
1.	Calcium alginate beads	Preparation from crosslinking by Ca^{2+} ions with alginate is applied in controlled release.	[48].
2.	Calcium phosphate beads	Biodegradable and targeting the bone.	[49].
3.	Silica beads	Used as carrier agents for hydrophobic drugs and for controlled release.	[50].
Based on Release Mechanism			
1.	Matrix beads	The drug is dispersed uniformly in the bead matrix, where it leaches out gradually as the matrix degrades.	[51].
2.	Reservoir beads	Drug encapsulated in a shell of a polymer, which will then be released either by diffusion or controlled erosion.	[52].
3.	Coated beads	The rate-controlling can be obtained by applying a polymer coating on beads.	[53].
Based on Route of Administration			

1.	Oral beads	Used for sustained release of drugs, targeted delivery for specific parts of the gastrointestinal tract, or masking unpleasant taste.	[54].
2.	Parenteral beads	Used for controlled release of drugs to be administered via injection, like insulin or growth factors.	[55].
3.	Mucosal beads	Used for drug delivery to mucous membranes through the nasal, oral, or vaginal cavities.	[56].
4.	Transdermal beads	Used for controlled drug delivery through the skin.	[57].

MANUFACTURING TECHNIQUES FOR BEAD FORMULATION

Extrusion and Spheronization

The primary application of extrusion spheronization is in the preparation of multiparticulates, which are small beads or pellets, to deliver some advantages of high bioavailability, reduced undesirable side effects, and increased stability. This process, most used, involves a mixture of APIs with APIs, excipients, and binders that will be processed through extrusion and spheronization to produce beads [58].

Key Steps in the Extrusion Spheronization Process [59]



Figure 2. Diagrammatic representation of the extrusion-spheronization process.

The wet mass or paste is prepared as the first step in the process of extrusion spheronization by mixing the API with an excipient, which can includes binders that hold the mass together (polyvinylpyrrolidone (PVP), hydroxypropyl methylcellulose (HPMC), maltodextrin), fillers that contribute to the weight of the formulation (like lactose and starch), disintegrants that cause the beads to disintegrate in the gastrointestinal tract include croscarmellose sodium and sodium starch glycolate. The dry mix is subjected to the addition of a suitable solvent, most commonly water or an aqueous solution, to form a cohesive wet mass. Addition of the solvent in the correct proportion is quite important to gain the right consistency for extrusion (Figure 2).

The wet mass is fed into an extruder; this could be a single-screw extruder or a twin-screw extruder. The wet mass is forced through the die in the extruder. This results in the material being produced in long strands or filaments. Therefore, the diameter of the produced extrudate depends on the size and shape of the die used. Key parameters during extrusion are speed, temperature, and size of the die screw. The extrudates are cut into pellets or small pieces, typically of length small enough to be conveniently passed through the opening of a pelletizer. The cut extrudates are placed into a spheronizer used in the preparation of spherical particles from irregularly shaped extrudates. Spheronizers can work through the aid of either a rotating plate or drum.

This mechanical action rolls up the edges of extrudates with each other to form spherical beads. Spheronization parameters: the speed, time, and moisture content may significantly determine the final characteristics of the beads. After spheronization, the produced beads are normally dried to remove all traces of moisture and obtain the desired mechanical strength. This can be achieved by using tray dryers, fluidized bed dryers. post-processing and coating is done depending on the desired application, including sieving, coating, and blending. This can be blended with other excipients or drugs for the final product according to the desired formulation.

Applications of Extrusion Spheronization in Pharmaceutical Bead Formulation [60–62]

1. Controlled-release formulations.
2. Improved solubility and bioavailability.
3. Taste masking.
4. Multiparticulate drug delivery systems.
5. Stability improvement.

Ionotropic Gelation

Among all the methods utilized to synthesize polymeric beads, the most widely used one is ionotropic gelation, often for encapsulating drugs within biodegradable or biocompatible materials like alginate, chitosan, or other polysaccharides. This method basically follows the process by which beads are formed through the cross-linking of polymer chains by multivalent ions, causing gelation. It is very simple and does not need organic solvents and thus is often used for encapsulation purposes of sensitive drugs, peptides, and proteins (Figure 3) [63].



Figure 3. Diagrammatic representation of the ionotropic gelation process.

Here's a Step-By-Step Description of the Process

Dissolve a suitable polysaccharide, such as sodium alginate, in deionized water. Typical concentrations are between 1% and 5% w/v, depending upon required viscosity and bead strength, respectively. Drug is dissolved or dispersed in the polymer solution. Based on the solubility of the drug, it can be either a solution or a suspension. Cross-linking solution is prepared by adding a cross-linking agent into water. For example, in the case of alginate beads, a $CaCl_2$ solution of 1%–2% w/v is normally used. For chitosan beads, TPP solution can serve as a cross-linker. The concentration of the solution should be appropriate to provide proper gelation. Polymer–drug solution is dropped dropwise into the cross-linking solution using a syringe or a precision needle. Ionic cross-linking rapidly gels the droplets as they fall into the cross-linking solution. The size of the beads can be controlled in this

method by altering the needle size or the rate of extrusion. Mechanical or air-assisted methods, such as air-jet extrusion or mechanical nozzles, that assist with the formation of uniform beads with defined sizes [64].

When the polysaccharide (e.g., alginate) solution meets the multivalent ions (e.g., Ca^{2+} from calcium chloride), the cross-linking ions bind to the carboxyl groups of the polymer, creating a three-dimensional gel network [65]. This rapid interaction leads to the formation of spherical beads. The beads are left to stand in the cross-linking solution for a specified period (usually 10–30 minutes) to ensure complete gelation and bead formation. The resultant beads are allowed to harden either by staying in the cross-linking solution or by being transferred into a secondary hardening solution to improve the mechanical strength. Once the beads have fully formed, they are gently taken out from the crosslinking solution through a sieve or filter, washed with deionized water or buffer to remove any remaining cross-linking ions or unreacted polymer, and then dried.

Applications [66]
1. Controlled and sustained drug release.
2. Encapsulation of sensitive molecules.
3. Targeted drug delivery.

Spray Drying

Spray drying is one of the most used processes in the pharmaceutical industry for the preparation of dry powder in the form of powders, granules, or beads through drying of a liquid or slurry in a hot gas. Spray drying can, therefore, be used in pharmaceutical bead formulation to obtain beads or microparticles useful for drug delivery systems when drugs need to be solubilized for optimal absorption or released slowly, or when preparing multiparticulate dosage forms. This method is particularly useful in making amorphous solid dispersions, enhancing drug bioavailability, and designing controlled-release formulations (Figure 4) [67].

Key Steps in the Spray Drying Process [68]



Figure 4. Diagrammatic representation of the spray drying process.

The initial step of spray drying is the preparation of the feed solution or suspension. This feed contains the API blended with one or more excipients like Polymers (HPMC, Eudragit, and PVP) forming the bead matrix, surfactants that facilitate its stabilization and increase hydrophobic drug solubility. Solvents for dissolving or dispersing API and excipients, which comprise water, ethanol, and acetone. Plasticizers, such as PEG and triacetin, are used to make the polymer matrix flexible. *Liquid Feed Formulation:* Formulation of liquid feed is an important part of the process. It determines

many characteristics of the dried beads, like particle size, drug loading, and release profile. Liquid feed is supplied to the spray dryer and atomized into fine droplets. Fine droplets generated by an atomizer are dosed into a chamber where they meet a hot drying gas, which is usually air or nitrogen. The temperature of the hot air shall vary with the requirements of chemical stability of the drug and excipients used, and generally ranges from 100°C to 200°C. The solvent-whether it is water or an organic solvent-evaporates fast, and this tends to leave behind solid particles or beads containing the drug and excipients as the droplets pass through the drying chamber. The atomized droplets are dried instantaneously; the solvent evaporates because of the drying gas, and in milliseconds to a few seconds, droplets turn into solid beads or particles. The inlet temperature is taken considering the heat sensitivity of the API. A lower drying temperature is applied when the API is sensitive to heat to avoid degradation. Such fixed beads or microparticles, after drying, are separated from the drying air by using cyclones or filters and collected in the powder collection chamber. The design of the drying chamber prevents agglomeration from happening during the process, hence providing free-flowing and discrete beads. Once the microparticles or beads have been collected, they may undergo further post-processing, that is sieving, blending to achieve the final properties.

Drug release may be controlled by applying a coat to the beads. Coating is done by applying functional polymers on the beads. The enteric coating may be cited as shielding off releasing drugs in the stomach, while hydrophobic coatings are used for sustained-release formulations.

Applications of Spray Drying in Pharmaceutical Bead Formulation [69]

1. Amorphous solid dispersions.
2. Controlled-release beads.
3. Encapsulation of sensitive drugs.
4. Multiparticulate drug delivery systems.
5. Taste masking.
6. Enteric-coated beads.

Hot Melt Extrusion (HME)

HME is a process combining versatility with advanced techniques of processing for the preparation of solid dispersions, formulation of controlled-release dosage forms, and enhancement of drug solubility. In HME, drugs are blended with a polymer matrix under the action of heat and mechanical shear and become a homogeneous molten mass to be extruded into filaments, rods, or beads. This method has gained significant attention from the pharmaceutical arena, especially in formulating sustained- or modified-release preparations (Figure 5) [70–72].

Key Steps of the HME Process [73]



Figure 5. Diagrammatic representation of HME process.

API: The drug is process-compatible, hence stable at the processing temperature and not prone to degradation.

Polymers are chosen based on their thermal stability and drug release profile. Some of the most used polymers in HME include Ethyl cellulose, Eudragit (polymethacrylate) PVP, Hydroxypropyl cellulose (HPC), Polyethylene glycol (PEG).

Triethyl citrate or propylene glycol plasticizers are used as plasticizers to reduce the processing temperature, increase polymer flexibility, and enhance the mechanical properties of the extrudates. Other excipients, like solubilizers, surfactants, or stabilizers, might be used to improve the solution of the drug during the dissolution process or avoid degradation before preparation. The raw materials, comprising API, polymer, plasticizer, among others, are fed into the extruder through a hopper. The feeding can be done with gravimetric feeders or volumetric feeders to ensure accurate and consistent input into the extruder. The feed material can be in the form of a powder, granule, or pellet. The core process of HME resides in the extruder itself, or a barrel and screws. Heating zones are designed into an extruder that raises the temperature along the length of the barrel. The temperature can be precisely controlled, varying from 50°C to over 200°C. This is dependent on the melting point of the polymer, along with the API. In the barrel, during movement, the material undergoes mechanical shear with the thermal energy provided by rotating screws. This shearing action helps the materials to get perfectly mixed up and melt, hence forming a homogeneous molten mass. Screw design is another critical step, which decides on the efficiency of mixing, melting, and conveying of the material. Twin-screw extruders are used primarily in pharmaceuticals since they can mix the materials more effectively than single-screw extruders. Once the material is melted and mixed well, it is then forced through an extrusion die, which gives the material a certain shape. The die may come in different designs and may produce filaments, rods, or small beads. For the pharmaceutical bead formulation, the die will typically be fitted with small orifices through which the molten material is extruded to come out in cylindrical shapes, which could then be further processed into spherical beads. After extruding, the molten material needs to be cooled for the shape that forms after extrusion to become solid. The drug–polymer matrix is allowed to solidify into a stable configuration during cooling. In this process, the drug is “frozen” into the polymer matrix. Once the extruded material has solidified, further processing may be required in a post-processing step to achieve a final bead formulation that includes spheronization, screening, and coating.

Applications of HME in Pharmaceutical Bead Formulation [74]

1. Controlled-release beads.
2. Solubility enhancement.
3. Fixed-dose combinations.
4. Taste masking.
5. Enteric coating.

MELT SOLIDIFICATION TECHNIQUE

The melt solidification process refers to a technique for pharmaceutical bead formulations to make solid dosage forms from melted excipients and APIs. Its advantage is also enhanced in improving the solubility of such poorly water-soluble drugs, enhancing bioavailability, and enabling controlled drug release. Below is a detailed explanation of the melt solidification process, including its principles, steps, and applications (Figure 6) [75–77].

Key Steps in the Melt Solidification Process [78]

Several APIs and excipients may be chosen depending upon the therapeutic behavior of an excipient, its compatibility with the API, and the desired characteristics of drug release. Excipients

most commonly used are Polymers, like PEG, PVP, and ethyl cellulose, and plasticizers, such as triethyl citrate or glycerin, that increase the flexibility and flowability of the melted mass. Fillers, like lactose or microcrystalline cellulose, are added to add bulk. Excipients chosen along with the drug API are mixed in a very controlled heating process till they melt homogeneously. This process can use hot melt extruders, melting pots, or ovens.

Continuous mixing of the melt mass is required to ensure a uniform API distribution in the excipient matrix. Appropriate mixing is needed; otherwise, one would run the risk of experiencing localized overheating and degradation. The resultant solution is then cooled to start the solidification of the liquid. This can be done with various methods like cooling baths and air cooling. The molten mass transforms from a liquid state to a solid state when it cools down. Solidified beads can be made by different processes of solidified beads. The beads are collected and would, depending on the application, maybe sieved to achieve a uniform particle size distribution. The formulation can receive further surface treatments, such as coating, to enhance the drug release profile or stability.



Figure 6. Diagrammatic representation of melt solidification process.

Applications of Melt Solidification Process (Table 2) [79]

- Improving solubility and bioavailability.
- Controlled-release formulations.
- Taste masking.
- Sustained-release beads.
- Granulation.

MATERIALS USED IN BEAD FORMULATION

Various categories of materials are utilized in the formulation of beads. Different types of beads require different excipients, which are described in Table 3.

Table 2. Comparison of bead formulation techniques based on advantages and challenges.

Method	Advantages	Challenges
Extrusion and spheronization [61, 62].	Uniformity in size and shape	Material compatibility
	Scalability	Moisture sensitivity
	Versatility	Thermal sensitivity
	Continuous process	Capital investment in equipment
	Improved flow properties	
Ionotropic gelation [65].	Mild conditions	Inconsistent particle size and shape
	Biocompatibility	Limited drug loading efficiency
	Controlled release	Crosslinking agent limitations
		Scalability issues
Spray drying [70, 71].	Rapid drying and high throughput	Thermal sensitivity
	Production of amorphous solid dispersions	Solvent recovery
	Versatility in formulation	Agglomeration
	Uniform particle size	Initial cost of equipment
	Solvent flexibility	
	Enhanced stability	
HME for bead formulation [75, 76].	Solvent-free process	Thermal degradation
	Enhanced drug solubility and stability	Polymer selection
	Continuous processing	High initial cost
	Customizable drug release	
	Wide range of formulations	
	Scalability	
Melt solidification process [80, 81].	Simplified process	Thermal sensitivity
	Scalability	Equipment costs
	Versatility	Compatibility
	Improved stability	

Table 3. Describing the various materials required for the formulation of beads.

S. N.	Category of Material	Examples	References
1.	Polymers		
	Natural	Carrageenan, pectin, tragacanth, gelatin, sodium alginate, alginic acid, guar gum, gellan gum, xyloglucan, pectin, and chitosan.	[82].
	Synthetic	Polystyrene, polypropylene, polyacrylate, polycarbonate, polymethacrylates.	[83, 84].
	Biodegradable polymers	Polylactones, polyglycolides, polycaprolactones, polyalkyl-cyanoacrylates, polyorthoesters, and polyphosphoesters.	[85].
2.	Gas-generating agents/ Floating agents	Citric acid, tartaric acid, or sodium bicarbonate.	[86, 87].
3.	Cross-linking agents	Barium chloride, calcium chloride, zinc chloride, barium sulphate, zinc sulphate.	[88].
4.	Magnetic substances	Fe_3O_4 particles	[89].

Applications of Pharmaceutical Beads

Pharmaceutically manufactured beads vary from extrusion spheronization, spray drying, or ionotropic gelation to many others. Pharmaceutical beads have an enormous range of applications in

the pharmaceutical and healthcare industries. Some of the significant uses of pharmaceutical beads are as follows:

1. ***Controlled Release of Drugs:***
   - *Sustained Release:* Beads can be designed to release the API over days, weeks, or months, reducing dosing frequency and improving patient compliance.
   - *Targeted Release:* Beads can be engineered to release the drug at specific GI tract locations, maximizing efficacy while minimizing side effects [90].
2. ***Improving Solubility and Bioavailability:***
   - *Improved Dissolution:* Beads enhance solubility by forming solid dispersions or increasing surface area.
   - *Bioavailability Enhancement:* Beads improve bioavailability by boosting solubility and dissolution rates [91].
3. ***Taste Masking:*** *Patient Compliance:* Beads mask unpleasant tastes, improving oral tolerance, especially in pediatric formulations [92].
4. ***Multiparticulate Systems:***
   - *Dose Uniformity:* Beads ensure even drug distribution for consistent dosing and effects.
   - *Reduced Dose Dumping:* Multiparticulate formulations prevent dose dumping, reducing adverse effects [93].
5. ***Pelletization for Oral Dosage Forms:***
   - *Tablet and Capsule Fillers:* Beads enable precise dosing and enhance formulation characteristics.
   - *Coating:* Additional layers on beads help achieve controlled release, ideal for complex formulations [94].
6. ***Stability Improvement:***
   - *Protection:* Beads protect sensitive drugs from moisture, light, and oxygen, enhancing stability and shelf life.
   - *Controlled Environment:* Encapsulation shields drugs from degradation during storage and transport [95].
7. ***Regenerative Medicine and Biomedical Applications:***
   - *Drug-Laden Scaffolds:* Beads will also be used as drug-loaded scaffolds in tissue engineering, which will enhance cell proliferation and regeneration of the tissue.
   - *Cell Encapsulation:* Pharmaceutical beads may be utilized as a carrier for the encapsulation of living therapeutic cells; examples include cell-based therapies and vaccine delivery [96].
8. ***Cosmetic and Nutraceutical Applications:***
   - *Nutraceutical Beads:* Encapsulate vitamins, minerals, and supplements for controlled release and absorption.
   - *Cosmetic Formulations:* Beads enable controlled release of actives, enhancing skin penetration and effectiveness [97].
9. ***Diagnostic Applications:***
   - *Imaging and Detection:* Beads can be functionalized to provide diagnostics applications, especially imaging agents or as carriers to administer diagnostic agents with a propensity to be targeted in medical imaging [98].
10. ***Vaccines and Immunotherapy:***
    - *Encapsulation:* Beads can encapsulate either antigens or adjuvants, thus improving stability and delivery of vaccines, which enhances the immune response [99].
11. ***Combination Therapies:***
    - *Multiple Drugs in One Formulation:* Beads enable different APIs with varied release profiles, improving combination therapy and patient adherence.
12. ***Sequential Drug Release:***
    - *Timed Release:* Beads allow the timed release of drugs for synergy or activation, optimizing therapeutic effects [100].

ADVANTAGES OF PHARMACEUTICAL BEADS

Pharmaceutical bead formulations offer several unique advantages that make them a preferred option for many drug delivery systems. Here are the key benefits:

1. *Modified Drug Release:* Beads enable controlled, sustained, or delayed release, reducing dosing frequency and maintaining stable therapeutic levels [101].
2. *Improved Stability:* Encapsulation protects sensitive drugs from environmental factors like light, moisture, and stomach acids, enhancing shelf life [102].
3. *Enhanced Patient Compliance:* Extended-release beads reduce dosing frequency, improving adherence for chronic treatments [103].
4. *Reduced GI Side Effects:* Enteric-coated beads prevent stomach irritation, releasing the drug in the intestine for better tolerance [104].
5. *Combination Therapy:* Beads allow multiple drugs with different release profiles in one dosage, simplifying treatment regimens [105].
6. *Uniform Drug Distribution:* Small beads ensure even dispersion in the GI tract, leading to consistent absorption and effect [106].
7. *Dose Flexibility:* Beads can be customized in size and drug load, supporting personalized medicine [107].
8. *Minimized Dose Dumping Risk:* Beads release medication in controlled amounts, preventing toxicity from sudden drug release [108].
9. *Formulation Versatility:* Beads can be incorporated into capsules, tablets, or suspensions, meeting diverse therapeutic needs [109].
10. *Taste and Odor Masking:* Encapsulation improves palatability, benefiting pediatric and geriatric patients [110, 111].

Challenges and Limitations in Bead Formulation

1. *Complex Manufacturing Process:* These intricate processes – layering, coating, and extrusion-spheronization – require precise control over particle size, drug distribution, and coating thickness. Achieving uniformity and consistency, especially in large-scale production, is challenging. Even minor variations can impact the drug release profile, potentially affecting therapeutic outcomes [112].
2. *High Production Costs:* Pharmaceutical bead preparation involves layering, coating, and extrusion-spheronization, requiring precise control over particle size, drug distribution, and coating thickness. Maintaining consistency in large-scale production is challenging, as minor variations can impact drug release and therapeutic outcomes [113].
3. *Limited Drug Loading Capacity:* Beads typically hold less drug than tablets or capsules, as the API is layered onto inert cores or within a coating matrix. This can be a drawback for high-dose drugs, making the dosage form impractically large [114].
4. *Coating Uniformity Issues:* Uniform bead coating is crucial for controlled release, but variations in thickness or composition can lead to dose dumping or suboptimal effects. Maintaining consistency is especially challenging in large-scale continuous production [115].
5. *Risk of Drug-Excipient Interactions:* Bead formulations require many excipients for controlled release, risking API interactions that may affect stability or bioavailability. Identifying suitable excipients demands extensive screening [116].
6. *Limited Use for Immediate-Release Formulations:* Indeed, while bead formulations are excellent for sustained or controlled release, they may not be as good for immediate-release products. A coating or a matrix that controls the drug release can delay the onset of action, and it may not provide appropriate actions for drugs, those being meant to act fast [117].
7. *Difficulties in Dose Adjustments:* Bead dosage adjustment is challenging compared to tablets or liquids, which can be easily split or measured. Capsules with beads require a complete formulation change for dose modifications [118].

8. *Potential for Decreased Patient Acceptability:* Bead-filled capsules may be difficult to swallow for dysphagic patients, making tablets or dissolvable forms preferable in some cases despite their sustained-release benefits [119].
9. *Intestinal Transit Variability:* Bead transit time varies with size, density, and feeding state, affecting absorption and drug efficacy, making pharmacokinetics harder to predict accurately [120].
10. *Stability Issues:* Bead formulations are prone to chemical degradation and stability issues, especially with biodegradable polymers, requiring extensive research to ensure shelf life and efficacy under storage conditions [121].
11. *Regulatory Challenges:* FDA and other regulators require extensive testing for bead formulations, especially with new technologies like nanomaterials or biodegradable polymers. Approval can be lengthy, costly, and more complex for personalized or combination therapies [122].

CHARACTERIZATION OF BEADS

A pharmaceutical beads evaluation ensures the quality and safety associated with them, as well as their effectiveness in drug delivery systems. Such an assessment process includes several characterization tests of beads, both physically, chemically, and biologically, along with performance. Some of the commonly performed assessments on pharmaceutical beads include the following:

Physical Characterization

- *Size and Shape [123]: Particle size distribution:* This is determined by sieve analysis or laser diffraction. Uniform size is necessary for uniform drug release as well as dosing.
- *Shape Analysis:* Inspection based upon optical microscope images or SEM images to determine the morphology and uniformity of the beads.
- *Surface Area: Surface area measurement:* Techniques, such as BET (Brunauer–Emmett–Teller) analysis, can determine the surface area, which affects the drug dissolution rate.
- *Density: Bulk density:* Mass of beads in a unit volume. Measured in a graduated cylinder.
- *Tapped Density:* Density of beads after tapping. Helpful in measuring flow properties.

Chemical Characterization [124]

- *Drug Content Analysis:* Determination of API: The content of the drug in the bead is estimated using HPLC or UV spectrophotometry, or any other suitable analytical method.
- *Release Profile:* In vitro drug release studies kinetics of drug release from the beads is studied over time usually by dissolution apparatus. Various media simulating physiological conditions can be used.
- *Stability Testing:* Long-term stability beads are exposed to controlled conditions and tested for drug content, release characteristics, and physical properties at different time intervals to observe stability.

Mechanical Characterization [125]

- *Hardness and Friability: Hardness testing:* This assesses the mechanical strength of the beads; in fact, this is crucial for ensuring that the beads are strong enough to endure handling and transport without cracking.
- *Friability Testing:* This evaluates the tendency for the beads to break under stress in a way that would ensure that they do not crumble during manufacturing and administration.
- *Flow Properties [126]: Angle of repose:* Angle up to which the beads can rest on a surface and not slide-a measure of flowability. *Cohesion and compressibility:* Standardized tests to test the ability of the beads to flow well during the manufacturing process.

Biological Evaluation [127]

- *In Vitro Biocompatibility: Cytotoxicity testing:* The beads must be tested for cytotoxic effects on cultured cells so that they would not adversely affect biological systems.

- *In Vivo Studies: Pharmacokinetic studies:* Animal studies must be done to check the bioavailability and distribution of the drug from the beads in the animal system.
- *Efficacy Studies:* Utilizing the therapeutic effects of the beads-delivery drug in preclinical models.

Thermal Characterization [128]
- *TGA:* This method is employed for the determination of weight changes in beads versus temperature, and thus to get both the stability and composition.
- *Differential Scanning Calorimetry (DSC):* This measures thermal transitions as melting and crystallization. These are useful transitions to study for the physical state and compatibility of the drug, as well as excipients.

Microscopic Examination [129]
- *SEM:* It will produce the surface morphologies and bead structures. In this regard, SEM shall be used to scrutinize the beads for most anomalies or flaws.
- *Optical Microscopy:* Qualitative observations related to size, the distribution of size, shape, and surface characteristics of beads.

Environmental Impact Assessment [130]
- *Moisture Content: Moisture sorption isotherm:* Determines moisture's effect on the stability and integrity of the beads, which then contributes to the importance of keeping product quality during storage.
- *pH stability:* Beads can be checked for their capability to remain stable across a pH range to prove if they function efficiently under alternative physiological conditions.

INNOVATIONS AND FUTURE TRENDS IN BEAD FORMULATION

1. *Nanotechnology in Bead Formulation:* Nanotechnology is revolutionizing bead preparations by enabling nanometer-scale beads that enhance drug solubility, targeted delivery, and absorption. Nanobeads improve drug precision, reducing side effects and boosting efficacy, especially in cancer therapies and gene delivery. Additionally, they facilitate theranostic applications by carrying both therapeutic and diagnostic agents [131].
2. *3D Printing of Pharmaceutical Beads:* 3D printing enables precise control over bead size, shape, and drug release profiles, allowing for complex release mechanisms and multilayered beads with multiple drugs. Its adaptability supports personalized therapies and accelerates drug development cycles [132].
3. *Biodegradable Beads:* Biodegradable beads dissolve naturally in the body, eliminating the need for surgical removal. They enable long-term drug release, making them ideal for chronic conditions, post-surgical care, orthopedics, cancer treatment, and tissue engineering, where sustained local therapy is essential [133].
4. *Personalized Medicine Using Beads:* Personalized medicine is embracing bead formulations tailored to an individual's genetics, lifestyle, or disease markers. These beads enable precise dosages and drug combinations for optimized treatment, especially in oncology and chronic diseases. Advanced diagnostics ensure targeted delivery at the right dose and time [134].

CONCLUSIONS

In conclusion, pharmaceutical beads are a very flexible and highly efficient drug delivery system, carrying many advantages over other traditional dosage forms. Their therapeutic control on the release of drugs, enhancement of stability of drugs, and augmentation of bioavailability, along with minimizing side effects, establishes the necessity of pharmaceutical beads in the world of modern pharmaceuticals. And as more technologies arise, especially nanotechnology and 3D printing, these beads will eventually take an even more significant role. They are waiting in the wings to contribute towards personalized medicine and targeted drug delivery to ensure that their treatment approaches meet individual needs for optimized efficacy and patient compliance. While some difficulties have been encountered in production and formulation, many advantages abound over pharmaceutical beads

in being able to be made to improve therapeutic outcomes and accommodate patient adherence, thereby, locking their continued significance in the pharmaceutical world.

REFERENCES

1. Rajabi-Siahboomi AR. Overview of multiparticulate systems for oral drug delivery. In: Multiparticulate Drug Delivery: Formulation, Processing and Manufacturing. 2017. p. 1–4.
2. Ramu S, Ramakrishna G, Balaji M, Kondala K, Haranadh S, Kumar D. Multiple unit drug delivery system: pelletization techniques. Am J Adv Drug Deliv. 2013;1(1):11–21.
3. Lee S, Kim MS, Jun SW, Park JS, Hwang SJ. Preparation of controlled release spheronized beads by a simple extrusion and modified spheronization process. Arch Pharm Res. 2005;28:619–25.
4. Prezotti FG, Cury BS, Evangelista RC. Mucoadhesive beads of gellan gum/pectin intended to controlled delivery of drugs. Carbohydr Polym. 2014;113:286–95.
5. Goldman P. Herbal medicines today and the roots of modern pharmacology. Ann Intern Med. 2001;135(8 Pt 1):594–600.
6. Zuo J, Park C, Kung JY, Bou-Chacra NA, Doschak M, Löbenberg R. Traditional Chinese medicine “pill”, an ancient dosage form with surprising modern pharmaceutical characteristics. Pharm Res. 2021;38:199–211.
7. Advankar A, Maheshwari R, Tambe V, Todke P, Raval N, Kapoor D, et al. Specialized tablets: Ancient history to modern developments. In: Drug delivery systems. Academic Press; 2019. p. 615–64.
8. Helfand WH, Cowen DL. Evolution of pharmaceutical oral dosage forms. Pharm Hist. 1983;25(1):3–18.
9. Oudshoorn N. The male pill: A biography of a technology in the making. Durham: Duke University Press; 2003.
10. Helfand WH, Cowen DL. Evolution of pharmaceutical oral dosage forms. Pharm Hist. 1983;25(1):3–18.
11. Lee PI, Li JX. Evolution of oral controlled release dosage forms. In: Oral controlled release formulation design and drug delivery: Theory to practice. 2010. p. 21–31.
12. Qiu Y, Zhang G. Development of modified-release solid oral dosage forms. In: Developing Solid Oral Dosage Forms. Academic Press; 2009. p. 501–17.
13. Bose S, Bogner RH. Solventless pharmaceutical coating processes: A review. Pharm Dev Technol. 2007;12(2):115–31.
14. O’Connor RE, Schwartz JB. Extrusion and spheronization technology. In: Pharmaceutical Pelletization Technology. CRC Press; 2022. p. 187–216.
15. Foroughi-Dahr M, Mostoufi N, Sotudeh-Gharebagh R, Chaouki J. Particle coating in fluidized beds. Ref Modul Chem Mol Sci Chem Eng. 2017:1–89.
16. Kamaly N, Yameen B, Wu J, Farokhzad OC. Degradable controlled-release polymers and polymeric nanoparticles: Mechanisms of controlling drug release. Chem Rev. 2016;116(4):2602–63.
17. Desai D, Wang J, Wen H, Li X, Timmins P. Formulation design, challenges, and development considerations for fixed dose combination (FDC) of oral solid dosage forms. Pharm Dev Technol. 2013;18(6):1265–76.
18. Seoane-Vazquez E, Rodriguez-Monguio R, Hansen R. Interchangeability, safety and efficacy of modified-release drug formulations in the USA: The case of opioid and other nervous system drugs. Clin Drug Investig. 2016;36:281–92.
19. Jinshad K, Pillai MK. Enteric coated effervescent micro bead drug delivery system: A better approach for pulsatile drug delivery to intestine. Res J Pharm Technol. 2019;12(8):4007–12.
20. Battaglia L, Ugazio E. Lipid nano- and microparticles: An overview of patent-related research. J Nanomater. 2019;2019(1):2834941.
21. Alruwaili NK, Rizwanullah M, Bukhari SN, Amir M, Ahmed MM, Fazil M. 3D printing technology in design of pharmaceutical products. Curr Pharm Des. 2018;24(42):5009–18.

22. Kapoor D, Maheshwari R, Verma K, Sharma S, Ghode P, Tekade RK. Coating technologies in pharmaceutical product development. In: Drug Delivery Systems. Academic Press; 2020. p. 665–719.
23. Banker GS, Siepmann J, Rhodes C. Sustained-and controlled-release drug-delivery systems. In: Modern Pharmaceutics. CRC Press; 2002. p. 768–810.
24. Shamma RN, Basalious EB, Shoukri RA. Development and optimization of a multiple-unit controlled release formulation of a freely water-soluble drug for once-daily administration. Int J Pharm. 2011;405(1–2):102–12.
25. Tran PH, Tran TT, Park JB, Lee BJ. Controlled release systems containing solid dispersions: Strategies and mechanisms. Pharm Res. 2011;28:2353–78.
26. Abouelatta SM, Aboelwafa AA, Khalil RM, ElGazayerly ON. Floating lipid beads for the improvement of bioavailability of poorly soluble basic drugs: In-vitro optimization and in-vivo performance in humans. Eur J Pharm Biopharm. 2015;89:82–92.
27. Brahmankar DM, Jaiswal SB. Biopharmaceutics and Pharmacokinetics: Pharmacokinetics. 2nd ed. Delhi: Vallabh Prakashan; 2009. p. 399–401.
28. Lee VHL. Controlled Drug Delivery Fundamentals and Applications: Influence of Drug Properties on Design. 2nd ed. New York: Marcel Dekker Inc.; 1987. p. 16–25.
29. Wani MS, et al. Controlled release system – A review [Internet]. 2008 [cited 2025 Jun 25]. Available at http://www.pharmainfo.net/reviews/controlled-released-system-review
30. Ho WH, Lee HLV. Sustained Drug Delivery Fundamentals and Applications: Design and fabrication of oral controlled release drug delivery system. 2nd ed. Marcel Dekker Inc, New York: 1987; 373–420p.
31. Kar RK, Mohapatra S, Barik BB. Design and characterization of controlled release matrix tablets of Zidovudine. Asian J Pharm Clin Res. 2009;2:54–6.
32. Guthmann C, Lipp R, Wagner T, Kranz H. Development of a novel osmotically driven drug delivery system for weakly basic drugs. Eur J Pharm Biopharm. 2008;69(2):667–74.
33. Forbes ZG, Yellen BB, Barbee KA, Friedman G. An approach to targeted drug delivery based on uniform magnetic fields. IEEE Trans Magn. 2003;39(5):3372–7.
34. Shi J, Liu X, Sun X, Cao S. Hybrid alginate beads with thermal-responsive gates for smart drug delivery. Polym Adv Technol. 2011;22(11):1539–46.
35. Jayakumar R, Reis RL, Mano JF. Synthesis and characterization of pH-sensitive thiol-containing chitosan beads for controlled drug delivery applications. Drug Deliv. 2007;14(1):9–17.
36. Martínez-Donato G, Piniella B, Aguilar D, Olivera S, Pérez A, Castañedo Y, et al. Protective T cell and antibody immune responses against hepatitis C virus achieved using a biopolyester-bead-based vaccine delivery system. Clin Vaccine Immunol. 2016;23(4):370–8.
37. Stöve J, Fiedler J, Huch K, Günther KP, Puhl W, Brenner R. Lipofection of rabbit chondrocytes and long lasting expression of a lacZ reporter system in alginate beads. Osteoarth Cartil. 2002;10(3):212–7.
38. Sharma KV, Dreher MR, Tang Y, Pritchard W, Chiesa OA, Karanian J, et al. Development of "imageable" beads for transcatheter embolotherapy. J Vasc Interv Radiol. 2010;21(6):865–76.
39. Rubin JP, Bennett JM, Doctor JS, Tebbets BM, Marra KG. Collagenous microbeads as a scaffold for tissue engineering with adipose-derived stem cells. Plast Reconstr Surg. 2007;120(2):414–24.
40. VanWijk MJ, VanBavel E, Sturk A, Nieuwland R. Microparticles in cardiovascular diseases. Cardiovasc Res. 2003;59(2):277–87.
41. Mohanraj VJ, Chen YJ. Nanoparticles—a review. Trop J Pharm Res. 2006;5(1):561–73.
42. Chrai SS, Murari R, Ahmad I. Liposomes: A review. Pharm Technol. 2002;26(4):28–34.
43. Croy SR, Kwon GS. Polymeric micelles for drug delivery. Curr Pharm Des. 2006;12(36):4669–84.

44. Kulkarni AR, Soppimath KS, Aminabhavi TM, Dave AM, Mehta MH. Glutaraldehyde crosslinked sodium alginate beads containing liquid pesticide for soil application. J Control Release. 2000;63(1–2):97–105.
45. Bodmeier R, Oh KH, Pramar Y. Preparation and evaluation of drug-containing chitosan beads. Drug Dev Ind Pharm. 1989;15(9):1475–94.
46. Lopes S, Bueno L, Aguiar FD, Finkler C. Preparation and characterization of alginate and gelatin microcapsules containing *Lactobacillus rhamnosus*. An Acad Bras Cienc. 2017;89(3):1601–13.
47. Kim CJ, Lee PI. Composite poly(vinyl alcohol) beads for controlled drug delivery. Pharm Res. 1992;9:10–6.
48. Agarwal T, Kabiraj P, Narayana GH, Kulanthaivel S, Kasiviswanathan U, Pal K, et al. Alginate bead based hexagonal close packed 3D implant for bone tissue engineering. ACS Appl Mater Interfaces. 2016;8(47):32132–45.
49. Fu YC, Ho ML, Wu SC, Hsieh HS, Wang CK. Porous bioceramic bead prepared by calcium phosphate with sodium alginate gel and PE powder. Mater Sci Eng C. 2008;28(7):1149–58.
50. Quang DV, Sarawade PB, Hilonga A, Kim JK, Chai YG, Kim SH, et al. Preparation of amino functionalized silica microbeads by dry method for supporting silver nanoparticles with antibacterial properties. Colloids Surf A Physicochem Eng Asp. 2011;389(1–3):118–26.
51. Wang F, Zhao J, Li W, Zhou H, Yang X, Sui N, et al. Preparation of several alginate matrix gel beads and their adsorption properties towards rare earths (III). Wast Biom Valoriz. 2013;4:665–74.
52. Lugtu-Pe JA, Lin BY, Chen K, Ghaffari A, Kane A, Wu XY. Tailoring release profiles of BCS class II drugs using controlled release amorphous solid dispersion beads with membrane-reservoir design: Effect of pore former and coating levels. Mol Pharm. 2021;18(11):4198–209.
53. Lee BJ, Min GH. Preparation and release characteristics of polymer-reinforced and coated alginate beads. Arch Pharm Res. 1995;18:183–8.
54. Sriamornsak P. Application of pectin in oral drug delivery. Expert Opin Drug Deliv. 2011;8(8):1009–23.
55. Bayomi MA, El-Sayed YM. Casein microbeads as a controlled parenteral drug delivery system. Drug Dev Ind Pharm. 1994;20(16):2607–17.
56. Swain S, Behera A, Beg S, Patra CN, Dinda SC, Sruti J, et al. Modified alginate beads for mucoadhesive drug delivery system: An updated review of patents. Recent Pat Drug Deliv Formul. 2012;6(3):259–77.
57. Lam PL, Gambari R. Advanced progress of microencapsulation technologies: In vivo and in vitro models for studying oral and transdermal drug deliveries. J Control Release. 2014;178:25–45.
58. Koester M, Thommes M. New insights into the pelletization mechanism by extrusion/spheronization. AAPS PharmSciTech. 2010;11:1549–51.
59. Trivedi NR, Rajan MG, Johnson JR, Shukla AJ. Pharmaceutical approaches to preparing pelletized dosage forms using the extrusion-spheronization process. Crit Rev Ther Drug Carrier Syst. 2007;24(1).
60. Dhandapani NV. Pelletization by extrusion-spheronization—a detailed review. All Results J Biol. 2012;3(2):10–23.
61. Jain SP, Pal Singh P, Amin PD. Alternative extrusion–spheronization aids. Drug Dev Ind Pharm. 2010;36(11):1364–76.
62. Ravetti S, Hergert LY, Sparo MD, Sanchez Bruni SF, Palma SD. Challenges in protein formulation focused on extrusion-spheronization process. Int J Pharm Res Rev. 2016;5(3):29–38.
63. Patil JS, Kamalapur MV, Marapur SC, Kadam DV. Ionotropic gelation and polyelectrolyte complexation: the novel techniques to design hydrogel particulate sustained, modulated drug delivery system: A review. Dig J Nanomater Biostruct. 2010;5(1):241–8.

64. Rakesh P, Vipin K, Kanchan K. Alginate beads prepared by ionotropic gelation technique: Formulation design. Res J Chem Sci. 2015;2231:606X.
65. Pedroso-Santana S, Fleitas-Salazar N. Ionotropic gelation method in the synthesis of nanoparticles/microparticles for biomedical purposes. Polym Int. 2020;69(5):443–7.
66. Sacco P, Pedroso-Santana S, Kumar Y, Joly N, Martin P, Bocchetta P. Ionotropic gelation of chitosan flat structures and potential applications. Molecules. 2021;26(3):660.
67. Santos D, Maurício AC, Sencadas V, Santos JD, Fernandes MH, Gomes PS. Spray drying: An overview. In: Biomaterials–Physics and Chemistry–New Edition. 2018:9–35.
68. Kemtchou VT, Schäfer M, Peuker UA. Synthesis of functionalized magnetic beads using spray drying. In: Upscaling of Bio-Nano-Processes: Selective Bioseparation by Magnetic Particles. Berlin: Springer; 2014. p. 97–116.
69. Okuyama K, Abdullah M, Lenggoro IW, Iskandar F. Preparation of functional nanostructured particles by spray drying. Adv Powder Technol. 2006;17(6):587–611.
70. Sosnik A, Seremeta KP. Advantages and challenges of the spray-drying technology for the production of pure drug particles and drug-loaded polymeric carriers. Adv Colloid Interface Sci. 2015;223:40–54.
71. Peighambardoust SH, Tafti AG, Hesari J. Application of spray drying for preservation of lactic acid starter cultures: A review. Trends Food Sci Technol. 2011;22(5):215–24.
72. Young CR, Koleng JJ, McGinity JW. Production of spherical pellets by a hot-melt extrusion and spheronization process. Int J Pharm. 2002;242(1–2):87–92.
73. Madan S, Madan S. Hot melt extrusion and its pharmaceutical applications. Asian J Pharm Sci. 2012;7(1).
74. Repka MA, Battu SK, Upadhye SB, Thumma S, Crowley MM, Zhang F, et al. Pharmaceutical applications of hot-melt extrusion: Part II. Drug Dev Ind Pharm. 2007;33(10):1043–57.
75. Andrews GP, Jones DS, Diak OA, Margetson DN, McAllister MS. Hot-melt extrusion: An emerging drug delivery technology. Pharm Technol Eur. 2009;21(1):18–24.
76. Verreck G, Vandecruys R, De Conde V, Baert L, Peeters J, Brewster ME. The use of three different solid dispersion formulations—melt extrusion, film-coated beads, and a glass thermoplastic system—to improve the bioavailability of a novel microsomal triglyceride transfer protein inhibitor. J Pharm Sci. 2004;93(5):1217–28.
77. Paradkar A, Maheshwari M, Tyagi AK, Chauhan B, Kadam SS. Preparation and characterization of flurbiprofen beads by melt solidification technique. AAPS PharmSciTech. 2003;4:514–22.
78. Maheshwari M, Ketkar AR, Chauhan B, Patil VB, Paradkar AR. Preparation and characterization of ibuprofen–cetyl alcohol beads by melt solidification technique: Effect of variables. Int J Pharm. 2003;261(1–2):57–67.
79. Kamble R, Maheshwari M, Paradkar A, Kadam S. Melt solidification technique: Incorporation of higher wax content in ibuprofen beads. AAPS PharmSciTech. 2004;5:75–83.
80. Sedighi M. Encapsulation: Melt dispersion. In: Principles of Biomaterials Encapsulation: Volume One. Woodhead Publishing; 2023. p. 213–34.
81. Becker K, Salar-Behzadi S, Zimmer A. Solvent-free melting techniques for the preparation of lipid-based solid oral formulations. Pharm Res. 2015;32:1519–45.
82. Prajapati VD, Jani GK, Khutliwala TA, Zala BS. Raft forming system—an upcoming approach of gastroretentive drug delivery system. J Control Release. 2013;168(2):151–65.
83. Aoki H, Iwao Y, Mizoguchi M, Noguchi S, Itai S. Clarithromycin highly-loaded gastro-floating fine granules prepared by high-shear melt granulation can enhance the efficacy of *Helicobacter pylori* eradication. Eur J Pharm Biopharm. 2015;92:22–7.
84. Patil H, Tiwari RV, Repka MA. Recent advancements in mucoadhesive floating drug delivery systems: A mini-review. J Drug Deliv Sci Technol. 2016;31:65–71.
85. Lohani A, Chaudhary G. Mucoadhesive microspheres: A novel approach to increase gastroretention. Chron Young Sci. 2012;3(2):121.

86. Sugihara H, Matsui Y, Takeuchi H, Wilding I, Connor A, Abe K, et al. Development of a gastric retentive system as a sustained-release formulation of pranlukast hydrate and its subsequent in vivo verification in human studies. Eur J Pharm Sci. 2014;53:62–8.
87. Garg RG, Gupta GD. Progress in controlled gastroretentive delivery systems. Trop J Pharm Res. 2008;7(3):1055–66.
88. Wang J, Tauchi Y, Deguchi Y, Morimoto K, Tabata Y, Ikada Y. Positively charged gelatin microspheres as gastric mucoadhesive drug delivery system for eradication of *H. pylori*. Drug Deliv. 2000;7(4):237–43.
89. Hilton AK, Deasy PB. In vitro and in vivo evaluation of an oral sustained-release floating dosage form of amoxycillin trihydrate. Int J Pharm. 1992;86(1):79–88.
90. Manjunatha KM, Ramana MV, Satyanarayana D. Design and evaluation of diclofenac sodium controlled drug delivery systems. Indian J Pharm Sci. 2007;69(3):384–9.
91. Ganesh M, Jeon UJ, Ubaidulla U, Hemalatha P, Saravanakumar A, Peng MM, et al. Chitosan cocrystals embedded alginate beads for enhancing the solubility and bioavailability of aceclofenac. Int J Biol Macromol. 2015;74:310–7.
92. Rajesh AM, Popat KM. Taste masking of ofloxacin and formation of interpenetrating polymer network beads for sustained release. J Pharm Anal. 2017;7(4):244–51.
93. Puranam DH, Yarguntla SR, Pulipaka S. An empirical approach to mitigate the risk of content uniformity variability during the tablet compression of drug coated extended release beads. Nveo-Nat Volat Essent Oils J. 2021;8(4):15422–35.
94. Hirjau M, Nicoara AC, Hirjau V, Lupuleasa D. Pelletization techniques used in pharmaceutical fields. Pract Farm. 2011;4(3):206–11.
95. Sankalia MG, Mashru RC, Sankalia JM, Sutariya VB. Papain entrapment in alginate beads for stability improvement and site-specific delivery: Physicochemical characterization and factorial optimization using neural network modeling. AAPS PharmSciTech. 2005;6:E209–22.
96. Popa EG, Gomes ME, Reis RL. Cell delivery systems using alginate–carrageenan hydrogel beads and fibers for regenerative medicine applications. Biomacromolecules. 2011;12(11):3952–61.
97. Bhattacharya P. A review on the impacts of microplastic beads used in cosmetics. Acta Biomed Sci. 2016;3(1):47–52.
98. Sukhanova A, Nabiev I. Fluorescent nanocrystal-encoded microbeads for multiplexed cancer imaging and diagnosis. Crit Rev Oncol Hematol. 2008;68(1):39–59.
99. Martínez-Donato G, Piniella B, Aguilar D, Olivera S, Pérez A, Castañedo Y, et al. Protective T cell and antibody immune responses against hepatitis C virus achieved using a biopolyester-bead-based vaccine delivery system. Clin Vaccine Immunol. 2016;23(4):370–8.
100. Adebisi AO, Laity PR, Conway BR. Formulation and evaluation of floating mucoadhesive alginate beads for targeting *Helicobacter pylori*. J Pharm Pharmacol. 2015;67(4):511–24.
101. Vikulina AS, Campbell J. Biopolymer-based multilayer capsules and beads made via templating: Advantages, hurdles and perspectives. Nanomaterials (Basel). 2021;11(10):2502.
102. Saha S, Kaushik K, Garg R. Formulation of smart hydrogel beads for pharmaceutical importance. Res J Pharm Technol. 2020;13(2):901–4.
103. Moinuddin SK, Kumar P, Kumar S, Ramya P, Sree KS, Kavya K. A review on micro beads: Formulation, technological aspects, and extraction. GSC Biol Pharm Sci. 2024;26(2):59–66.
104. Mohamed MA, El-Deeb NM, El-Assar MR, Farag MM, Ahmed AF. Elusive pharmaceutical function of multi-advantages drug delivery system from natural mushroom. Al-Azhar Bull Sci. 2018;29(2-C):19–25.
105. Setia M, Kumar K, Teotia D. Gastro-retentive floating beads: A new trend of drug delivery system. J Drug Deliv Ther. 2018;8(3):169–80.
106. Burgos-Ramos E, Martos-Moreno GÁ, Argente J, Barrios V. Multiplexed bead immunoassays: Advantages and limitations in pediatrics. In: Advances in Immunoassay Technology. 2012. p. 165–80.

107. Ranganath SH, Kee I, Krantz WB, Chow PK, Wang CH. Hydrogel matrix entrapping PLGA-paclitaxel microspheres: Drug delivery with near zero-order release and implantability advantages for malignant brain tumour chemotherapy. Pharm Res. 2009;26:2101–14.
108. Jedinger N, Khinast J, Roblegg E. The design of controlled-release formulations resistant to alcohol-induced dose dumping–a review. Eur J Pharm Biopharm. 2014;87(2):217–26.
109. Hu L, Kong D, Hu Q, Yang X, Xu H. Preparation and optimization of a novel microbead formulation to improve solubility and stability of curcumin. Part Sci Technol. 2017;35(4):448–54.
110. Panahi HA, Feizbakhsh A, Khaledi S, Moniri E. Fabrication of new drug imprinting polymer beads for selective extraction of naproxen in human urine and pharmaceutical samples. Int J Pharm. 2013;441(1–2):776–80.
111. Villanova JC, Ayres E, Carvalho SM, Patrício PS, Pereira FV, Oréfice RL. Pharmaceutical acrylic beads obtained by suspension polymerization containing cellulose nanowhiskers as excipient for drug delivery. Eur J Pharm Sci. 2011;42(4):406–15.
112. Fernando PA, Kennedy AJ, Pokrzywinski K, Jernberg J, Thornell T, George G, et al. Development of alginate beads for precise environmental release applications: A design of experiment based approach and analysis. J Environ Manage. 2024;351:119872.
113. Zayed MS. Advances in formulation development technologies. In: Microbial Inoculants in Sustainable Agricultural Productivity: Vol. 2: Functional Applications. 2016:219–37.
114. Sriamornsak P, Nunthanid J, Cheewatanakornkool K, Manchun S. Effect of drug loading method on drug content and drug release from calcium pectinate gel beads. AAPS PharmSciTech. 2010;11:1315–9.
115. Singh G, Nenavathu BP. Development of rGO encapsulated polymeric beads as drug delivery system for improved loading and controlled release of doxycycline drug. Drug Dev Ind Pharm. 2020;46(3):462–70.
116. Ansari M, Sadarani B, Majumdar A. Colon targeted beads loaded with pterostilbene: Formulation, optimization, characterization and in vivo evaluation. Saudi Pharm J. 2019;27(1):71–81.
117. Rani M, Agarwal A, Negi YS. Chitosan based hydrogel polymeric beads–as drug delivery system. BioResources. 2010;5(4):2765–807.
118. RM A, Mangesh RB, Rahul RP, Nilkanth SP, Devaki CU. Formulation and optimization of drug-resin complex loaded mucoadhesive chitosan beads of repaglinide using factorial design. Am J Med Med Sci. 2012;2(4):62–70.
119. Jain SK, Jain A, Gupta Y, Ahirwar M. Design and development of hydrogel beads for targeted drug delivery to the colon. AAPS PharmSciTech. 2007;8(3):56.
120. Arica B, Çaliş SE, Atİlla PE, Durlu NT, Cakar N, Kaş HS, et al. In vitro and in vivo studies of ibuprofen-loaded biodegradable alginate beads. J Microencapsul. 2005;22(2):153–65.
121. Patil S, Sharma S, Nimbalkar A, Pawar A. Study of formulation variables on properties of drug-gellan beads by factorial design. Drug Dev Ind Pharm. 2006;32(3):315–26.
122. O'Brien MN, Jiang W, Wang Y, Loffredo DM. Challenges and opportunities in the development of complex generic long-acting injectable drug products. J Control Release. 2021;336:144–58.
123. Vino S, Paryani P, Ghosh AR. Formulation and evaluation of chitosan beads of levocetirizine dihydrochloride. J Appl Pharm Sci. 2012;2(8):221–5.
124. Sharma M. Formulation and evaluation of sodium alginate beads by emulsion gelation method. Asian J Pharm. 2017;11(1):101–6.
125. Mishra SK, Pathak K. Formulation and evaluation of oil entrapped gastroretentive floating gel beads of loratadine. Acta Pharm. 2008;58(2):187–97.
126. Tous S, Fathy M, Fetih G, Gad SF. Preparation and evaluation of ketoprofen-loaded calcium alginate beads. Int J PharmTech Res. 2014;6(3):1100–12.

127. Abdellatif AA, El Hamd MA, Saleh K. A formulation, optimization and evaluation of controlled released alginate beads loaded-flurbiprofen. J Nanomed Nanotechnol. 2016;7(357):2.
128. Li Y, Fan Y, Ma J. The thermal properties of porous polydivinylbenzene beads. React Funct Polym. 2002;50(1):57–65.
129. Neves MA, Coutinho FM, Dias ML, Simão RA, Achete CA. Surface morphology evaluation of polymer beads based on divinylbenzene by atomic force microscopy. J Appl Polym Sci. 2002;84(3):541–51.
130. Khan MS, Sridhar BK, Srinatha A. Development and evaluation of pH-dependent micro beads for colon targeting. Indian J Pharm Sci. 2010;72(1):18.
131. Thakur RS, Agrawal R. Application of nanotechnology in pharmaceutical formulation design and development. Curr Drug Ther. 2015;10(1):20–34.
132. Ahmadzadeh S, Ubeyitogullari A. Fabrication of porous spherical beads from corn starch by using a 3D food printing system. Foods. 2022;11(7):913.
133. Nofar M, Ameli A, Park CB. A novel technology to manufacture biodegradable polylactide bead foam products. Mater Des. 2015;83:413–21.
134. Ahmed MU, Saaem I, Wu PC, Brown AS. Personalized diagnostics and biosensors: A review of the biology and technology needed for personalized medicine. Crit Rev Biotechnol. 2014;34(2):180–96.
135. Janos B, Klara P, Odon P, Geza RJ, Rok D, Stane S, et al. Film coating as a method to enhance the preparation of tablets from dimenhydrinate crystals. Int J Pharm. 2004; 269:393–401.

